Modalis Therapeutics Corporation

4883

JP3922600006

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 31/05/2024 BST			5-day change	1st Jan Change
69 ^JPY	-1.43%		-.--%	-44.35%

05-07	Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	CI
04-30	Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	CI

EdiGENE Corporation Names Dong Wei as Its Chief Executive Officer

August 02, 2018 at 02:51 am

EdiGENE Corporation announced that it has named Dong Wei as its chief executive officer. Most recently, Dr. Dong Wei was Chief Operating Officer at Treos Bio.

Latest news about Modalis Therapeutics Corporation

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101	05-07	CI
Modalis Therapeutics Corporation to Present Data Supporting Development of Transformative Epigenome Editing Medicines for the Treatment of Muscular Dystrophy at the Global Cell & Gene Therapy Summit	04-30	CI
Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs	04-15	MT
Modalis Therapeutics to Reduce Stated Capital and Capital Reserves	02-23	MT
Japanese Shares Continue to Track Wall Street Higher as Investor Caution Ahead of US Rate Decision Caps Gains	12-13	MT
Modalis Therapeutics, JCR Pharmaceuticals Form Drug Delivery Research Partnership	12-13	MT
Modalis Therapeutics Corporation and JCR Pharmaceuticals Enter into Joint Research Agreement	12-12	CI
Modalis Therapeutics Corporation announced that it has received ¥505.320864 million in funding from Evolution Capital Management LLC	11-29	CI
Modalis Therapeutics Corporation announced that it expects to receive ¥505.320864 million in funding from Evolution Capital Management LLC	11-06	CI
Modalis Therapeutics Corporation cancelled the transaction announced on September 11, 2023	27/09/23	CI
Modalis Therapeutics Corporation announced that it expects to receive ¥18.77952 million in funding from China Silver Asset Management Hong Kong Limited	10/09/23	CI
Modalis Therapeutics Corporation to Regain Full Rights to MDL-201 and MDL-202 from Astellas Pharma Inc	07/08/23	CI
Modalis Therapeutics Corporation Receives Positive FDA Response for Pre-IND Review for MDL-101 Clinical Development	26/06/23	CI
Modalis Therapeutics to Grant Stock Options	16/06/23	MT
Modalis Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Modalis Therapeutics Corporation to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of A Type of Muscular Dystrophy At the ASGCT Annual Meeting	19/04/23	CI
Modalis to Allot Stock Options	29/03/23	MT
Modalis Therapeutics to Overcome 2.6 Billion Yen Deficit in Retained Earnings	23/02/23	MT
Modalis Therapeutics Corporation Announces Notice of Termination of A Research Collaboration on 205	12/01/23	CI
Modalis Therapeutics Corporation(TSE:4883) dropped from S&P Global BMI Index	19/09/22	CI
Modalis Therapeutics Issues Share Acquisition Rights	06/07/22	MT
Modalis Therapeutics to Issue Share Acquisition Rights	16/06/22	MT
Modalis Therapeutics Swings to Loss in Q1 on Growing Research Costs	10/05/22	MT
Modalis Therapeutics Adds Cardiomyopathy Therapy to In-House Pipeline	10/05/22	MT
Modalis Therapeutics Corporation Announces Addition of MDL-105 to In-house Pipelines	09/05/22	CI

Chart Modalis Therapeutics Corporation

Duration

Period

More charts

Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
MODALIS THERAPEUTICS CORPORATION	-44.35%	16.44M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	114B
REGENERON PHARMACEUTICALS, INC.	+11.60%	105B
BIONTECH SE	-4.68%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-17.47%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.75B
SAREPTA THERAPEUTICS, INC.	+34.58%	11.76B

Bio Therapeutic Drugs

Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Biotechnology & Medical Research

EdiGENE Corporation Names Dong Wei as Its Chief Executive Officer

Latest news about Modalis Therapeutics Corporation

Chart Modalis Therapeutics Corporation

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs